Laquinimod for multiple sclerosis.
Cochrane database of systematic reviews, August 2013
He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S, He, Dian, Han, Kai, Gao, Xiangdong, Dong, Shuai, Chu, Lan, Feng, ZhanHui, Wu, Shan, Dian He, Kai Han, Xiangdong Gao, Shuai Dong, Lan Chu, ZhanHui Feng, Shan Wu
Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not all MS patients respond adequately to currently available disease-modifying drugs (DMDs). Alternative MS treatments with new modes of action are required to expand the current options for disease-modifying therapies (DMTs) and to aim for freedom from relapses, inflammatory lesions, disability progression and neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection and is a potentially promising new oral DMD in the treatment of relapsing MS.
|Members of the public||3||60%|
|Practitioners (doctors, other healthcare professionals)||1||20%|
|Readers by professional status||Count||As %|
|Student > Master||23||18%|
|Student > Ph. D. Student||15||12%|
|Student > Bachelor||12||9%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||50||38%|
|Nursing and Health Professions||12||9%|
|Biochemistry, Genetics and Molecular Biology||3||2%|